Philadelphia University + Thomas Jefferson University

Den, Robert

< Back

Profile

Robert B. Den, MD

Robert B. Den, MD

Contact Dr. Den

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6702
(215) 955-0412 fax

Research & Clinical Interests

I am a board-certified radiation oncologist who specializes in the treatment of prostate cancer. I see patients and discuss their cases in a genitourinary multidisciplinary clinic with colleagues in urology and medical oncology. I specialize in using IMRT to treat men with prostate cancer to improve patients outcomes and decrease the side effects of treatment. 

I am also a translational researcher with a laboratory at Jefferson that focuses on combining new biologic agents with radiation therapy. The goal of this work is to introduce the most exciting compounds into clinical trials to benefit my patients.

Publications

Most Recent Peer-Reviewed Publications

  1. Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle
  2. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer
  3. Utilizing 10-Year Results From the American Board of Radiology Clinical Examination to Identify Areas for Programmatic Improvement
  4. Current perspectives on bone metastases in castrate-resistant prostate cancer
  5. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer
  6. Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study
  7. Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017
  8. Process Mapping and Time Study to Improve Efficiency of New Procedure Implementation for High-Dose Rate Prostate Brachytherapy
  9. Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities
  10. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer
  11. Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer
  12. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup
  13. Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy
  14. The role of genomic techniques in predicting response to radiation therapy
  15. Increasing faculty participation in resident education and providing cost-effective self-assessment module credit to faculty through resident-generated didactics
  16. Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model
  17. Individual patient-level meta-Analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease
  18. Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes
  19. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality
  20. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer